147 related articles for article (PubMed ID: 34298713)
1. Oral Metronomic Maintenance Therapy Can Improve Survival in High-Risk Neuroblastoma Patients Not Treated with ASCT or Anti-GD2 Antibodies.
Sun X; Zhen Z; Guo Y; Gao Y; Wang J; Zhang Y; Zhu J; Lu S; Sun F; Huang J; Cai R; Zhang Y; Liu J; Xiao Z; Zeng S; Liu Z
Cancers (Basel); 2021 Jul; 13(14):. PubMed ID: 34298713
[TBL] [Abstract][Full Text] [Related]
2. Lack of survival advantage with autologous stem-cell transplantation in high-risk neuroblastoma consolidated by anti-GD2 immunotherapy and isotretinoin.
Kushner BH; Ostrovnaya I; Cheung IY; Kuk D; Modak S; Kramer K; Roberts SS; Basu EM; Yataghene K; Cheung NK
Oncotarget; 2016 Jan; 7(4):4155-66. PubMed ID: 26623730
[TBL] [Abstract][Full Text] [Related]
3. Prolonged progression-free survival after consolidating second or later remissions of neuroblastoma with Anti-G
Kushner BH; Ostrovnaya I; Cheung IY; Kuk D; Kramer K; Modak S; Yataghene K; Cheung NK
Oncoimmunology; 2015 Jul; 4(7):e1016704. PubMed ID: 26140243
[TBL] [Abstract][Full Text] [Related]
4.
Kushner BH; LaQuaglia MP; Modak S; Wolden SL; Basu EM; Roberts SS; Kramer K; Yataghene K; Cheung IY; Cheung NV
Oncotarget; 2017 Nov; 8(56):95293-95302. PubMed ID: 29221128
[TBL] [Abstract][Full Text] [Related]
5. The Role of Autologous Stem-Cell Transplantation in High-Risk Neuroblastoma Consolidated by anti-GD2 Immunotherapy. Results of Two Consecutive Studies.
Mora J; Castañeda A; Flores MA; Santa-María V; Garraus M; Gorostegui M; Simao M; Perez-Jaume S; Mañe S
Front Pharmacol; 2020; 11():575009. PubMed ID: 33324208
[No Abstract] [Full Text] [Related]
6. Long term outcome of high-risk neuroblastoma patients after immunotherapy with antibody ch14.18 or oral metronomic chemotherapy.
Simon T; Hero B; Faldum A; Handgretinger R; Schrappe M; Klingebiel T; Berthold F
BMC Cancer; 2011 Jan; 11():21. PubMed ID: 21244693
[TBL] [Abstract][Full Text] [Related]
7. Survival Benefit of Myeloablative Therapy with Autologous Stem Cell Transplantation in High-Risk Neuroblastoma: A Systematic Literature Review.
Żebrowska U; Balwierz W; Wechowski J; Wieczorek A
Target Oncol; 2024 Mar; 19(2):143-159. PubMed ID: 38401028
[TBL] [Abstract][Full Text] [Related]
8. Naxitamab Combined with Granulocyte-Macrophage Colony-Stimulating Factor as Consolidation for High-Risk Neuroblastoma Patients in First Complete Remission under Compassionate Use-Updated Outcome Report.
Mora J; Castañeda A; Gorostegui M; Varo A; Perez-Jaume S; Simao M; Muñoz JP; Garraus M; Larrosa C; Salvador N; Lavarino C; Krauel L; Mañe S
Cancers (Basel); 2023 Apr; 15(9):. PubMed ID: 37174002
[TBL] [Abstract][Full Text] [Related]
9. Autologous stem cell transplantation in first remission is associated with better progression-free survival in multiple myeloma.
Aggarwal M; Agrawal N; Yadav N; Verma P; Ahmed R; Mehta P; Kapoor J; Bhurani D
Ann Hematol; 2018 Oct; 97(10):1869-1877. PubMed ID: 29781040
[TBL] [Abstract][Full Text] [Related]
10. Metronomic topotecan impedes tumor growth of MYCN-amplified neuroblastoma cells in vitro and in vivo by therapy induced senescence.
Taschner-Mandl S; Schwarz M; Blaha J; Kauer M; Kromp F; Frank N; Rifatbegovic F; Weiss T; Ladenstein R; Hohenegger M; Ambros IM; Ambros PF
Oncotarget; 2016 Jan; 7(3):3571-86. PubMed ID: 26657295
[TBL] [Abstract][Full Text] [Related]
11. Achievement of at least very good partial response is a simple and robust prognostic factor in patients with multiple myeloma treated with high-dose therapy: long-term analysis of the IFM 99-02 and 99-04 Trials.
Harousseau JL; Avet-Loiseau H; Attal M; Charbonnel C; Garban F; Hulin C; Michallet M; Facon T; Garderet L; Marit G; Ketterer N; Lamy T; Voillat L; Guilhot F; Doyen C; Mathiot C; Moreau P
J Clin Oncol; 2009 Dec; 27(34):5720-6. PubMed ID: 19826130
[TBL] [Abstract][Full Text] [Related]
12. High-dose therapy and autologous stem cell transplantation in patients with diffuse large B-cell lymphoma in first complete or partial remission.
Papajik T; Raida L; Faber E; Vondrakova J; Prochazka V; Kubova Z; Skoumalova I; Jarosova M; M LK; Paucek B; Myslivecek M; Neoral C; Oral I; Jarkovsky J; Dusek L; Indrak K
Neoplasma; 2008; 55(3):215-21. PubMed ID: 18348654
[TBL] [Abstract][Full Text] [Related]
13. Quantitation of GD2 synthase mRNA by real-time reverse transcriptase polymerase chain reaction: clinical utility in evaluating adjuvant therapy in neuroblastoma.
Cheung IY; Lo Piccolo MS; Kushner BH; Kramer K; Cheung NK
J Clin Oncol; 2003 Mar; 21(6):1087-93. PubMed ID: 12637475
[TBL] [Abstract][Full Text] [Related]
14. Retrospective analysis of the efficacy and influencing factors of autologous hematopoietic stem cell transplantation for multiple myeloma.
Zhang BL; Zhou J; Lin QD; Liu YZ; Zhang YL; Gui RR; Song YP; Fang BJ
Artif Organs; 2019 Oct; 43(10):1028-1034. PubMed ID: 30972806
[TBL] [Abstract][Full Text] [Related]
15. Complete remission status before autologous stem cell transplantation is an important prognostic factor in patients with multiple myeloma undergoing upfront single autologous transplantation.
Kim JS; Kim K; Cheong JW; Min YH; Suh C; Kim H; Jo DY; Ryoo HM; Yoon SS; Lee JH;
Biol Blood Marrow Transplant; 2009 Apr; 15(4):463-70. PubMed ID: 19285634
[TBL] [Abstract][Full Text] [Related]
16. [Efficacy and Influencing Factors of Autologous Hematopoietic Stem Cell Transplantation for Multiple Myeloma: Retrospective Analysis].
Zhang BL; Zhou J; Zhang GL; Gui RR; Lin QD; Zu YL; Yu FC; Zhao HF; Li Z; Wang J; Fu YW; Zhang LN; Zhou H; Fang BJ; Song YP
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2018 Oct; 26(5):1414-1419. PubMed ID: 30295260
[TBL] [Abstract][Full Text] [Related]
17. [Comprehensive protocol for diagnosis and treatment of childhood neuroblastoma--results of 45 cases].
Tang JY; Pan C; Chen J; Xu M; Chen J; Xue HL; Gu LJ; Dong R; Ye H; Zhou M; Wang YP
Zhonghua Er Ke Za Zhi; 2006 Oct; 44(10):770-3. PubMed ID: 17229383
[TBL] [Abstract][Full Text] [Related]
18. [Treatment options and prognosis in newly diagnosed multiple myeloma patients].
Wang L; Tang W; Wang Y; Xu L; Zhao WL; Wu W; Chen YB; Shen ZX; Hu J
Zhonghua Xue Ye Xue Za Zhi; 2011 May; 32(5):308-12. PubMed ID: 21729598
[TBL] [Abstract][Full Text] [Related]
19. [Long-term follow-ups of comprehensive therapies for stage 4 neuroblastoma].
Zhang A; Pan C; Ye Q; Zhou M; Chen J; Luo C; Wang J; Tang Y; Xue H; Shen S; Tang J
Zhonghua Yi Xue Za Zhi; 2014 May; 94(20):1547-52. PubMed ID: 25146742
[TBL] [Abstract][Full Text] [Related]
20. Neuroblastoma in adolescents and adults: the Memorial Sloan-Kettering experience.
Kushner BH; Kramer K; LaQuaglia MP; Modak S; Cheung NK
Med Pediatr Oncol; 2003 Dec; 41(6):508-15. PubMed ID: 14595707
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
